These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 11558493)

  • 1. Mycophenolate mofetil monotherapy in liver transplantation.
    Stewart SF; Hudson M; Talbot D; Manas D; Day CP
    Lancet; 2001 Feb; 357(9256):609-10. PubMed ID: 11558493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion to combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy for renal dysfunction in liver transplant patients: never too late?
    Beckebaum S; Cicinnati VR
    Dig Dis Sci; 2011 Jan; 56(1):4-6. PubMed ID: 21049289
    [No Abstract]   [Full Text] [Related]  

  • 4. Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal.
    Neau-Cransac M; Morel D; Bernard PH; Merville P; Revel P; Potaux L; Saric J
    Clin Transplant; 2002 Oct; 16(5):368-73. PubMed ID: 12225434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study.
    Schlitt HJ; Barkmann A; Böker KH; Schmidt HH; Emmanouilidis N; Rosenau J; Bahr MJ; Tusch G; Manns MP; Nashan B; Klempnauer J
    Lancet; 2001 Feb; 357(9256):587-91. PubMed ID: 11558484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors.
    Barrera Pulido L; Alamo Martínez JM; Pareja Ciuró F; Gómez Bravo MA; Serrano Díez-Canedo J; Bernal Bellido C; Suárez Artacho G; García González I; Pascasio Acevedo JM; Bernardos Rodríguez A
    Transplant Proc; 2008 Nov; 40(9):2985-7. PubMed ID: 19010168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New immunosuppressive agents in clinical use: mycophenolate mofetil and tacrolimus.
    Hunt SA
    Cardiol Rev; 2000; 8(3):180-4. PubMed ID: 11174892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of mycophenolate mofetil against nephrotoxicity and hepatotoxicity induced by tacrolimus in Wistar rats.
    Ferjani H; El Arem A; Bouraoui A; Achour A; Abid S; Bacha H; Boussema-Ayed I
    J Physiol Biochem; 2016 Jun; 72(2):133-44. PubMed ID: 26746208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.
    Penninga L; Wettergren A; Chan AW; Steinbrüchel DA; Gluud C
    Cochrane Database Syst Rev; 2012 Mar; (3):CD008852. PubMed ID: 22419339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil monotherapy in stable liver transplant recipients with progressive renal failure.
    Detry O; De Roover A; Honoré P; Delwaide J; Jacquet N; Meurisse M
    Transplant Proc; 2002 May; 34(3):782-3. PubMed ID: 12034182
    [No Abstract]   [Full Text] [Related]  

  • 11. Conversion from calcineurin inhibitors to mycophenolate mofetil in liver transplant recipients with diabetes mellitus.
    Herrero JI; Quiroga J; Sangro B; Pardo F; Rotellar F; Cienfuegos JA; Prieto J
    Transplant Proc; 2003 Aug; 35(5):1877-9. PubMed ID: 12962832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
    Karie-Guigues S; Janus N; Saliba F; Dumortier J; Duvoux C; Calmus Y; Lorho R; Deray G; Launay-Vacher V; Pageaux GP
    Liver Transpl; 2009 Sep; 15(9):1083-91. PubMed ID: 19718632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
    Yoshida EM; Marotta PJ; Greig PD; Kneteman NM; Marleau D; Cantarovich M; Peltekian KM; Lilly LB; Scudamore CH; Bain VG; Wall WJ; Roy A; Balshaw RF; Barkun JS
    Liver Transpl; 2005 Sep; 11(9):1064-72. PubMed ID: 16123958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus and mycophenolate mofetil after liver transplantation.
    Kniepeiss D; Iberer F; Grasser B; Schaffellner S; Tscheliessnigg KH
    Transpl Int; 2003 Jul; 16(7):504-9. PubMed ID: 12687325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side effects and efficacy of renal sparing immunosuppression in pediatric liver transplantation-A single center matched cohort study.
    Leiskau C; Rajanayagam J; Pfister ED; Goldschmidt I; Junge N; Karch A; Lerch C; Richter N; Lehner F; Schrem H; Baumann U
    Pediatr Transplant; 2018 Aug; 22(5):e13207. PubMed ID: 29729061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil as induction therapy after liver transplantation.
    McDiarmid SV
    Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S85-9. PubMed ID: 10431021
    [No Abstract]   [Full Text] [Related]  

  • 19. Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection.
    Cantin B; Giannetti N; Parekh H; Panchal SN; Kwok BW; Najem R; Woodman K; Hunt SA; Valantine HA
    Clin Transplant; 2002 Jun; 16(3):196-201. PubMed ID: 12010143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction.
    Koch RO; Graziadei IW; Schulz F; Nachbaur K; Königsrainer A; Margreiter R; Vogel W
    Transpl Int; 2004 Oct; 17(9):518-24. PubMed ID: 15365603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.